|Articles|March 30, 2021

Oral Dose Design and Development

Author(s)Catalent

Catalent is the global leader in drug development and delivery, offering innovative development and manufacturing solutions for oral dosage forms.

Catalent is the global leader in drug development and delivery and offers partners comprehensive solutions in development, dose design, and manufacturing. Its phase-appropriate technologies and expertise ensure that the right decisions are made at each stage of development, creating oral dose forms that can help improve a drug’s clinical efficacy and commercial success.

OptiDose Design Solution™ offers customers the combination of Catalent’s wide-ranging approach to drug development, coupled with the broadest selection of advanced drug delivery technologies and manufacturing platforms available.

Catalent’s OptiDose Design Solution provides comprehensive drug design assessment that considers a holistic review of the molecule, patient, and market considerations. By evaluating drug design considerations including developability, manufacturability, differentiation, and patient needs, Catalent’s scientific advisors provide options to inform dose form decisions that can help create a successful treatment for all stakeholders.

From its global network of facilities, Catalent offers accelerated early drug development, proven bioavailability enhancement solutions, advanced drug delivery technologies, and flexible manufacturing of a variety of oral dose forms, including RP Scherer® softgel technology, Zydis® orally disintegrating tablets, modified-release capsules, and FlexDoseSM stick packs.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.